Navigation Links
Delpor Announces Issuance of US Patent Covering its Novel Implantable Device for the Long-Term Delivery of Antipsychotics and other Drugs
Date:3/7/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office issued on February 7, 2017 U.S. Patent No. 9,561,352 covering Delpor’s implantable device for the long-term delivery of therapeutic agents. The device uses Delpor’s proprietary PROZOR™ technology for the sustained release of drugs for several months after subcutaneous implantation. Delpor has several product candidates in development, including a 6-month formulation of risperidone and a 3-month formulation of olanzapine, that are covered by the newly issued patent.

Numerous therapeutic agents including risperidone, olanzapine, asenapine, and other CNS molecules can benefit from long-term sustained delivery. The benefits of such delivery include improved medication adherence, as well as a “smooth” pharmacokinetic profile resulting in enhanced safety and tolerability. Most CNS drugs, as well as other important classes, exhibit poor water solubility at neutral pH, creating challenges to the development of implantable sustained delivery systems which rely on passive diffusion as the primary drug release mechanism. Delpor’s proprietary PROZOR technology enables the release of antipsychotics and other agents for several months through passive diffusion, based on a unique formulation. Furthermore, Delpor’s drug delivery implant device, offers full reversibility if treatment discontinuation is needed due to adverse events.

“The issuance of this patent recognizes the novelty of the underlying technology and marks the beginning of a new family of patents for Delpor, making it a key component of our intellectual property portfolio,” said Tassos Nicolaou, President and CEO of Delpor. “The PROZOR technology overcomes the solubility challenges faced by most CNS drugs, and creates the potential for several sustained release long acting therapeutic products, lasting as long as one year. Our lead risperidone program is currently utilizing this unique approach to create a 6-month formulation of the drug which should result in superior clinical outcomes through improved medication adherence.”

Tassos Nicolaou continued: “If treatment discontinuation is needed due to adverse events, the implant can be easily removed by a healthcare professional, and drug plasma levels drop to zero within a day. Our goal is to further expand the use of this innovative platform for the delivery of other agents including the antipsychotics olanzapine and asenapine”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at http://www.delpor.com.

About PROZOR™
Delpor’s PROZOR technology enables the sustained release of certain insoluble drugs (including most antipsychotics) from a non-mechanical (passive) implantable drug delivery device based on a unique formulation. A typical formulation is a mixture of the drug and a group of excipients designed to regulate the pH over time. The formulation is in the form of an aqueous suspension held within a small cylindrical reservoir fitted at each end with conventional membranes.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/DelporUSPatentIssuance/032017/prweb14124829.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Isabel Healthcare Announces Integration of American Academy of Pediatrics (AAP) Pediatric Care Online™ (PCO) Resources with Isabel Professional
2. Pearson Announces Career Exploration Mentorship Program for Students, Young Professionals with Disabilities
3. CUBA Beverage Company Announces the Launch of New 100% Natural Alkaline Water Product
4. Alliance Healthcare Foundation Announces 26 Recipients of 2017 Mission Support Grant Program
5. OrthAlign, Inc. Announces Full Commercial Launch of UniAlign™, the World’s First Handheld Navigation Device for Use in Unicompartmental Knee Arthroplasty
6. Pearson Announces SXSWedu Conference 2017 Lineup
7. MyTrimLine Announces, Good Day PA to Use Nadia as the Show’s Nutritional Consultant
8. Fiberstar Announces Winners of the Citri-Fi® 125 Citrus Fiber Student Innovation Contest Supporting the Food and Beverage Industry
9. GAO RFID Announces a New Long Range Personnel Tracking System
10. Aloria Health Announces Opening Of Residential Services
11. ACMA Announces New Release of Compass Directional Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
Breaking Medicine Technology: